14.0 APPENDICES 
A. Additional Pre-clinical Data 
1. Pharmacokinetics of GM-CSF Secretion by Transduced Murine Tumor Cells 
2. Toxicity Studies of Mice Injected with GM-CSF Expressing 
Tumor Cells 
3. Relevant Publications 
4. Additional Immunologic Studies 
B. Production of Recombinant Virus for Clinical Studies 
1. Overview: Structure of vector, characteristics of packaging cells 
2. Generation of psi-CRIP and psi-CRIP-huGM-CSF Master Stocks 
3. Large scale production of recombinant virus 
4. Characterization of Master Stock Virus and production lots for 
helper virus and contamination with other agents 
5. Potential use of a modified MFG vector in the clinical protocol 
C. Protocol for preparation of human RCC vaccine 
D. Performance Status Evaluation 
E. Toxicity Evaluation Criteria: Local 
F. Toxicity Evaluation Criteria: Systemic 
G. Consent Forms 
H. Patient and Family Information on the Phase I Study 
I. Case Report/Clinical Data Forms 
15.0 REFERENCES 
[288] 
Recombinant DNA Research, Volume 17 
